Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant. The award covers 11,530 options with an exercise price of $3.01 per share, granted on October 12, 2025.
The options vest 100% on the first anniversary of the grant date and become exercisable on October 12, 2026, with an expiration on October 12, 2035. Following the transaction, the reporting person held 11,530 derivative securities, reported as Direct (D) ownership.
Traws Pharma, Inc. (TRAW) filed a Form 4 disclosing a director stock option grant. On 10/12/2025, the reporting person acquired 11,530 stock options at a $3.01 exercise price. The options vest 100% on the first anniversary of the grant date and expire on 10/12/2035. Following the transaction, 11,530 derivative securities were beneficially owned on a direct basis.
Traws Pharma (TRAW) reported an insider equity grant. CEO and Director Iain Dukes received a stock option for 64,839 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following the grant, 64,839 derivative securities were beneficially owned, held directly. The filing reflects a routine equity compensation award.
Traws Pharma (TRAW) reported an insider equity award. The company’s Chief Medical Officer filed a Form 4 disclosing a grant of 32,406 stock options on 10/12/2025 with an exercise price of $3.01 per share. The options vest 100% on the first anniversary of the grant date (10/12/2026) and carry an expiration date of 10/12/2035. The filing lists 32,406 derivative securities beneficially owned following the transaction, held under direct ownership.
Traws Pharma (TRAW) reported an insider equity award. Chief Operating Officer and Director Nikolay Savchuk was granted a stock option for 22,435 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. The filing lists the holdings as Direct (D). This is a routine compensatory grant disclosed on Form 4.
Traws Pharma (TRAW) reported an insider equity award. On 10/01/2025, a company director received a stock option grant covering 15,609 shares of common stock at an exercise price of $1.89 per share.
The options expire on 10/01/2035 and were reported with a derivative security price of $0. The award vests over three years from the grant date: 33% on the first anniversary, 33% on the second, and 34% on the third. The filing lists direct (D) ownership following the transaction.
Traws Pharma (TRAW) filed a Form 3 for director John Leaman, reporting initial beneficial ownership status as of 10/01/2025.
The filing states that no securities are beneficially owned. This is a routine Section 16 compliance disclosure establishing the insider’s baseline holdings at the time he became a reporting person.
Traws Pharma (TRAW) announced a clinical milestone via an 8-K: on October 14, 2025, the company dosed the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment candidate for newly diagnosed COVID subjects. The company furnished a press release as Exhibit 99.1.
This update signals progression into mid-stage testing for ratutrelvir, with details provided in the accompanying press release.
Traws Pharma, Inc. is soliciting proxies for its 2025 Annual Meeting to be held virtually on
The Board recommends voting For each director nominee, For the auditor ratification, For the plan amendment, and Every Two Years for say-on-pay frequency. The plan amendment requests an increase of
Traws Pharma, Inc. filed an 8-K describing board and leadership updates. On October 1, 2025, the Board appointed John Leaman, MD as an independent director with a term expiring at the 2025 annual meeting of stockholders, and added him to the Audit Committee. His compensation will match that of other non-employee directors under the company’s disclosed director pay program, and there are no related-party arrangements or transactions noted in connection with his appointment.
The Board also removed the “interim” designations from the titles of Dr. Iain Dukes and Charles Parker, who now serve as Chief Executive Officer and Chief Financial Officer, respectively. Mr. Parker continues to provide CFO services as a non-employee consultant through Stout, for which the company pays $500 per hour, up to a maximum of $50,000 per month. A press release dated October 6, 2025, was furnished as an exhibit.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
